Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yves Allory

Showing results (161-170 of 208) with videos related to

Pageof 21
Sort By:
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 20, 2016
Inflammatory-Related Genetic Variants in Non-Muscle-Invasive Bladder Cancer Prognosis: A Multimarker Bayesian AssessmentAlexandra Masson-Lecomte, Evangelina López de Maturana, Michael E Goddard, et al.
European Urology Focus|July 30, 2017
Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic ReviewPierre-Jean Lamy, Yves Allory, Anne-Sophie Gauchez, et al.
British Journal of Cancer|December 22, 2022
The Neuropilin-1/PKC axis promotes neuroendocrine differentiation and drug resistance of prostate cancerCharly Blanc, Anissa Moktefi, Ariane Jolly, et al.
Oncogene|March 22, 2023
Epigenomic mapping identifies an enhancer repertoire that regulates cell identity in bladder cancer through distinct transcription factor networksHélène Neyret-Kahn, Jacqueline Fontugne, Xiang Yu Meng, et al.
Nature Genetics|November 14, 2006
Regional copy number-independent deregulation of transcription in cancerNicolas Stransky, Céline Vallot, Fabien Reyal, et al.
Cancer Research|January 9, 2020
Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid FeaturesMiriam Marqués, Robin Tranchant, Blanca Risa-Ebrí, et al.
Clinical Genitourinary Cancer|March 23, 2021
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 StudyStéphane Culine, Aude Fléchon, Gwenaelle Gravis, et al.
European Urology Oncology|April 22, 2025
Oncological Safety and Diagnostic Yield of Percutaneous Needle-core Biopsies in Upper Tract Urothelial Carcinoma: The UPERCUT StudyDoriane Prost, Atanas Pachev, Eric De Kerviler, et al.
European Urology|June 28, 2023
Proteogenomic Characterization of Bladder Cancer Reveals Sensitivity to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand in FGFR3-mutated TumorsClarice S Groeneveld, Virginia Sanchez-Quiles, Florent Dufour, et al.
European Urology Oncology|July 14, 2026
FGFR3 Testing in Urothelial Carcinoma: An Expert Commentary on Best Practices From Patient Identification to Result ReportingEva M Compérat, Arndt Hartmann, Yves Allory, et al.
Pageof 21

Showing results (161-170 of 208) with videos related to

Sort By:
Pageof 21
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 20, 2016
Inflammatory-Related Genetic Variants in Non-Muscle-Invasive Bladder Cancer Prognosis: A Multimarker Bayesian AssessmentAlexandra Masson-Lecomte, Evangelina López de Maturana, Michael E Goddard, et al.
European Urology Focus|July 30, 2017
Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic ReviewPierre-Jean Lamy, Yves Allory, Anne-Sophie Gauchez, et al.
British Journal of Cancer|December 22, 2022
The Neuropilin-1/PKC axis promotes neuroendocrine differentiation and drug resistance of prostate cancerCharly Blanc, Anissa Moktefi, Ariane Jolly, et al.
Oncogene|March 22, 2023
Epigenomic mapping identifies an enhancer repertoire that regulates cell identity in bladder cancer through distinct transcription factor networksHélène Neyret-Kahn, Jacqueline Fontugne, Xiang Yu Meng, et al.
Nature Genetics|November 14, 2006
Regional copy number-independent deregulation of transcription in cancerNicolas Stransky, Céline Vallot, Fabien Reyal, et al.
Cancer Research|January 9, 2020
Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid FeaturesMiriam Marqués, Robin Tranchant, Blanca Risa-Ebrí, et al.
Clinical Genitourinary Cancer|March 23, 2021
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 StudyStéphane Culine, Aude Fléchon, Gwenaelle Gravis, et al.
European Urology Oncology|April 22, 2025
Oncological Safety and Diagnostic Yield of Percutaneous Needle-core Biopsies in Upper Tract Urothelial Carcinoma: The UPERCUT StudyDoriane Prost, Atanas Pachev, Eric De Kerviler, et al.
European Urology|June 28, 2023
Proteogenomic Characterization of Bladder Cancer Reveals Sensitivity to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand in FGFR3-mutated TumorsClarice S Groeneveld, Virginia Sanchez-Quiles, Florent Dufour, et al.
European Urology Oncology|July 14, 2026
FGFR3 Testing in Urothelial Carcinoma: An Expert Commentary on Best Practices From Patient Identification to Result ReportingEva M Compérat, Arndt Hartmann, Yves Allory, et al.
Pageof 21